Compare GFI & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFI | IQV |
|---|---|---|
| Founded | 1887 | 1982 |
| Country | South Africa | United States |
| Employees | 6628 | 93000 |
| Industry | Precious Metals | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.7B | 35.1B |
| IPO Year | N/A | 2013 |
| Metric | GFI | IQV |
|---|---|---|
| Price | $32.28 | $207.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 16 |
| Target Price | $52.71 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 3.5M | 1.4M |
| Earning Date | 03-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $49.67 | $6.77 |
| Revenue Next Year | N/A | $5.89 |
| P/E Ratio | ★ $25.02 | $123.30 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $23.86 | $154.50 |
| 52 Week High | $61.52 | $247.05 |
| Indicator | GFI | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 67.14 |
| Support Level | $31.69 | $159.91 |
| Resistance Level | $35.83 | $226.63 |
| Average True Range (ATR) | 0.98 | 5.07 |
| MACD | 0.13 | -0.58 |
| Stochastic Oscillator | 21.74 | 100.00 |
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia, and Peru. In Peru, the company also produces copper. The company is involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing, and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith, and South Deep, and surface-only open pit mining at Damang, Tarkwa, and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.